
Doctors Report the First Pregnancy Using a New AI Procedure
Doctors at Columbia University Fertility Center have reported what they are calling the first pregnancy using a new AI system, in a couple that had been trying to start a family for nearly two decades.
The pregnancy was possible due to an advance developed by the Columbia team, led by Dr. Zev Williams, director of the center, to address azoospermia, or a lack of detectable sperm in the ejaculate. Male factors account for about 40% of infertility in the U.S., and azoospermia is responsible for about 10% of those cases. Until recently, there was little doctors could do to address the lack of sperm needed to fertilize an egg, other than using donor sperm.
While to the naked eye, a sperm sample from a man with azoospermia might look normal, the microscope tells a different story, Williams says. Highly trained technicians rarely find any sperm in these samples, which are often filled with other debris. Add to that the fact that sperm are the smallest cell in the body, and it's not surprising that even the best fertility technicians rarely find sperm in azoospermia samples.
That's where AI comes in. Williams and his team spent five years developing a system that combined an AI algorithm for detecting sperm with a fluidic chip that passed the semen sample through a tiny tubule on a plastic chip. If the AI picked up sperm, that tiny portion of semen would be directed to a separate tubule and collected. The few sperm isolated in this way could then be stored, frozen, or used to fertilize an egg.
Called STAR, for Sperm Track and Recovery, the system was inspired by similar approaches that astrophysicists use to enlist AI to detect new stars and planets. 'If you can look into a sky that's filled with billions of stars and try to find a new one, or the birth of a new star, then maybe we can use that same approach to look through billions of cells and try to find that one specific one we are looking for,' says Williams. In this case, STAR is trained to pick up 'really, really, really rare sperm,' he says. 'I liken it to finding a needle hidden within a thousand haystacks. But it can do that in a couple of hours—and so gently that the sperm that we recover can be used to fertilize an egg.'
STAR is distinct from AI systems that have been developed to scan and detect specific features, Williams says, because it combines that analysis with the ability to also actively isolate the target in question—in this case, any sperm found in a semen sample. The system can scan eight million images in about an hour, and Williams remembers the moment when he was convinced that STAR could become a powerful tool for treating certain forms of infertility. 'To test the system, before we discarded samples where embryologists could not find any sperm, we decided to run those samples through the system. The embryologists really worked hard to find sperm, since they didn't want to be outshone by a machine. In one of the samples they analyzed for two days and found no sperm, STAR found 44 in an hour.'
Rosie and her husband became the first couple to get pregnant using STAR in March 2025. The couple spent nearly 19 years trying to get pregnant, and Rosie—who asked to use a pseudonym to protect her privacy—says their Orthodox Jewish faith kept them hopeful during 15 unsuccessful IVF cycles. Prior to the pregnancy, they had explored multiple options to address her husband's azoospermia, including surgery and enlisting an expert from overseas to manually analyze and isolate sperm from his samples. They also researched efforts to extract sperm that were more controversial because they involved using chemicals that could potentially be detrimental to the quality of sperm.
'There really was nothing else out there,' says Rosie, 38, of their options before learning about STAR. 'Especially because I am running quite a few years ahead of where we should be [for fertility]. I'm not that old, but in fertility years—egg-wise—I was reaching my end.'
They were introduced to Williams and his fertility program through a community group and learned everything they could about the system. 'We knew exactly what it was, and knew what they were trying to do,' says Rosie. 'If they could get sperm in a more natural way without chemicals and hopefully chose the good ones—if the program was able to do that, we knew we had a better chance.'
For the couple, using STAR did not require any additional testing or procedures; their successful cycle in March proceeded no differently than any of the other IVF cycles they had experienced. 'We were keeping our hopes to a minimum after so many disappointments,' says Rosie. 'We came in, did what we had to do for the cycle, knowing there was probably a very small chance of anything happening. Why should this be any different from every other time?'
Usually in an IVF cycle, there are far more sperm than eggs, says Williams, but in cases of azoospermia, the opposite is true. So to ensure that a couple has the best chance of a pregnancy, Williams and his team collect several batches of sperm using STAR and freeze them. Then they coordinate the mother-to-be's ovulation cycle on IVF, and on the day they retrieve her eggs, they collect a fresh semen sample, run it through STAR, and use any sperm collected to fertilize any available eggs. The frozen sperm serve as backup in case no fresh sperm can be found.
Within two hours after collecting her husband's sperm that March, they learned that Rosie's eggs had been successfully fertilized and were ready to be transferred to her uterus. 'After the transfer, it took me two days to believe I was actually pregnant,' says Rosie.
Now four months along, Rosie is receiving standard obstetric care, and all indications are that her pregnancy is proceeding well. 'I still wake up in the morning and can't believe if this is true or not,' she says. 'And I still don't believe [I'm pregnant] until I see the scans.'
Williams says azoospermia is only one of many infertility issues that AI could address. 'There are things going on that we are blind to right now. But with the introduction of AI, we are being shown what those things are. The dream is to develop technologies so that those who are told 'you have no chance of being able to have a child' can now go on to have healthy children.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Psychedelic Science 2025 Unveils Science, Studies & Trials Tracks Showcasing Next Generation in Brain Imaging, Clinical Trials, and Neuroplasticity
• Sessions cover the latest updates in psychedelic neuroscience, from psilocybin's effects on brain connectivity to trial design, clinical outcomes for PTSD, depression, addiction, and OCD, and the future of drug development through translational models and AI innovations • Speakers include globally renowned experts like Gabrielle Agin-Liebes, Ph.D., Michael Bogenschutz, M.D., Robin Carhart-Harris, Ph.D., Alan K. Davis, Ph.D., Gül Dölen, M.D., Ph.D., Ben Kelmendi, M.D., Franklin King, M.D., Amy Lehrner, Ph.D., Leslie Morland, Psy.D., David Nutt, Ph.D., Stephen Ross, M.D., Emmanuelle Schindler, M.D., Ph.D., and Nolan Williams, M.D. • Representing institutions include Columbia, CU Denver, Imperial College London, Johns Hopkins, LSU, Massachusetts General Hospital, NYU, Ohio State, Stanford, UC Berkeley, UCSD, UCSF, University of Alabama, University of New Mexico, University of Washington, and numerous VA centers DENVER, June 11, 2025 (GLOBE NEWSWIRE) -- Psychedelic Science 2025 (PS2025), the world's leading conference on psychedelic research, medicine, policy, and culture hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), announced its Science, Studies, and Trials tracks—three of the conference's most anticipated and data-rich offerings. Taking place June 16–20, 2025, at the Colorado Convention Center in Denver, PS2025's research tracks will convene top clinical investigators, neuroscientists, biotech pioneers, and social scientists to present a comprehensive and cross-disciplinary view of this transformative field of study. At a time when the global mental health crisis continues to grow, PS2025 showcases therapeutic research using psychedelic compounds such as psilocybin, MDMA, LSD, DMT, 5-MeO-DMT, and ketamine, which are being investigated as treatments for serious mental illnesses such as addiction, depression, PTSD, obsessive-compulsive disorder, as well as neurological conditions such as pain, Alzheimer's, Lyme Disease, and Parkinson's. Beyond clinical trials, PS2025 also offers the latest in psychedelic neuroscience, examining data from studies using new neuroimaging, cellular, and molecular research tools that deepen the understanding of the biological mechanisms underlying their remarkable effects. Social science research is also included that examines the usage, attitudes, and experiences of trial participants, psychedelic consumers, and the general public, providing important context for societal views about this rapidly growing field. 'With the science and understanding of psychedelic substances expanding exponentially in recent years, we're honored to welcome some of the world's top academic researchers to PS2025 so they can share this new knowledge with attendees from around the globe.'— Philippe Lucas, Ph.D., Director, Research & Safe Access, MAPS The Science, Studies, and Trials tracks will feature both senior research leaders as well as emerging voices from public and private universities throughout North America, as well as international institutions in the UK, Europe, and Latin America. This highly anticipated convergence allows scientists to engage deeply about hot topics, including durability of efficacy, safety and risk, placebo dynamics, the role of psychotherapy, transdiagnostic effects, precision psychiatry, biological mechanisms, novel compounds, and the role of government grants and private capital in innovation. Visit to view the full schedule, register for workshops, and explore hotel and travel options. Workshop spaces are limited and available on a first-come basis. Featured sessions in the Science, Studies, and Trials tracks include:20 Years of Human Neuroscience Research with PsychedelicsDavid Nutt, Ph.D., reflects on two decades of pioneering work using brain imaging and neuropharmacology to explore consciousness, depression, and psychedelic mechanisms of action. Psychedelic Frontiers at the National Institutes of Health: NIH-funded Studies, Research Opportunities, and PrioritiesJoin a conversation moderated by Stacy Fischer, M.D., featuring Michael Bogenschutz, M.D., and Patrick Finan, Ph.D., as they unpack the latest NIH-funded studies, explore future research opportunities, and discuss the evolving priorities shaping this rapidly growing field of psychedelic-assisted therapy. Frontiers in Psilocybin Research for OCD: Neural Mechanisms, Treatment Response, and Clinical ImplicationsIn a session moderated by Jamila Hokanson, M.D., Ben Kelmendi, M.D., and Terence Ching, Ph.D., explore cutting-edge research on psilocybin's neural effects, clinical outcomes, and its potential as a treatment for OCD. Studies of Psychedelic-Assisted Therapy for Addiction DisordersJoin a conversation with Matthew Johnson, Ph.D., and Rayyan Zafar, Ph.D., moderated by Peter Hendricks, Ph.D., for a discussion on the latest research into the use of psychedelics as tools to treat addiction. This session will explore emerging evidence, clinical insights, and the challenges and promises of integrating psychedelic-assisted therapy into addiction treatment frameworks. Psychedelic Therapy for Military Veterans: A New Paradigm of Healing the Wounds of WarModerated by Chris Stauffer, M.D., and featuring Allie Kaigle, PharmD, BCPP, Amy Lehrner, Ph.D., and Leslie Morland, Psy.D., this session examines how psychedelic-assisted therapies are reshaping the landscape of care for Veterans grappling with PTSD, depression, and moral injury. By combining cutting-edge research with lived experience, these experts reveal how these innovative therapies can unlock hope, resilience, and lasting healing for those who have Outcomes from a Trial of Psilocybin-Assisted Therapy for Major Depressive DisorderIn this presentation, Alan K. Davis, Ph.D., shares groundbreaking findings from a long-term follow-up study examining the sustained effects of psilocybin-assisted therapy for individuals with major depressive disorder and what these results mean for the future of psychedelic treatments in mental health care. Ayahuasca: Bridging Molecular and Clinical Insights – A Multidisciplinary PanelDráulio Araújo, Ph.D., moderates a conversation with Fernanda Palhano-Fontes, Ph.D., Marcelo Falchi Parra Carvalho Silva, M.D., and Marcelo Leite, Ph.D., on the multifaceted world of ayahuasca through a unique convergence of molecular research, clinical practice, and traditional wisdom. The conversation offers insights into ayahuasca's molecular mechanisms and its applications in healing trauma and supporting personal growth. Developing Ibogaine for Opioid Use Disorder: Bridging Science, Public Benefit, and Sacred RootsSusan Ousterman moderates a conversation with Jeremy Weate, Ph.D., Ryan Rich, and Peter Hendricks, Ph.D., on the journey of ibogaine from traditional medicine to modern addiction therapy. Together, they'll explore clinical advancements, regulatory challenges, and how to ethically integrate indigenous knowledge and practices to address the opioid epidemic. Improving Standardization and Reducing Bias in Psychedelic Drug Development Trials Using an AI-Enabled PlatformJennifer Tippett, Psy.D., and Danielle Schlosser, Ph.D., discuss how artificial intelligence can transform psychedelic research by improving standardization, reducing bias, and enhancing data quality in clinical trials. Discover how this innovative approach is shaping the next generation of rigorous, ethical, and effective psychedelic drug development. The Potential for Psychedelic-Assisted Therapy in Conflict-Affected Populations: Ukraine and the BalkansModerated by Tadeusz Hawrot and featuring Oksana Gryshchenko, Elise Wilson, Zina Besirevic, Ph.D., and Galyna Pidpruzhnykova, Ph.D., this panel explores how psychedelic-assisted therapies might offer pathways to healing for individuals and communities affected by war and Differences in Therapeutic Outcomes Between Synthetic Psilocybin and Whole Psilocybe Mushrooms: A Qualitative StudyJoin Pamela Kryskow, M.D., and Joseph La Torre, Ph.D., as they present their qualitative study exploring the participants' lived experiences and perceptions, offering a deeper understanding of how these distinct forms of psilocybin influence healing, integration, and personal transformation. The Unique Challenges and Potential for Studying Psychedelic-Assisted Therapy for Palestinians and Jews in IsraelModerated by Keren Tzarfaty, Ph.D., MFT, and featuring Adar Avnon, Sidi Ronen, Ph.D., and Clinical Psychologist Wasim Biroumi, this session dives into the promise and complexities of researching psychedelic-assisted therapy in the unique socio-political landscape of Israel. The panel will discuss how shared trauma and cultural dynamics shape therapeutic approaches and the role psychedelics may play in fostering healing, understanding, and resilience across Outcomes from Yale's Real-World Psilocybin Trial: Connecticut-Funded Pioneering Psychedelic Therapy Program and Insights from Other State InitiativesJesse MacLachlan and Gabrielle Agin-Liebes, Ph.D., share findings from Yale's groundbreaking psilocybin trial, the first state-funded psychedelic therapy program in the U.S. This session will examine the transdiagnostic benefits observed in real-world settings and highlight key insights from Connecticut's initiative alongside other state-led programs shaping the future of psychedelic-assisted Critical Periods and Cephalopods: A Conversation with Neuroscientist Dr. Gül DölenJoin Gül Dölen, M.D., Ph.D., and Amy Emerson for a fascinating conversation that spans critical periods in brain development and the remarkable learning abilities of cephalopods. This session will illuminate the connections between these insights and the potential of psychedelics to re-open windows of plasticity in the adult brain. Listening to Lead: How a Community-Informed Psilocybin Study is Guiding New Mexico's Regulated ModelCrystal Romero, Janus Herrera, Dara Menashi, Ph.D., Larry Leeman, M.D., and Hanifa Nayo Washington (moderator) explore how New Mexico's historic Senate Bill 219 is paving the way for the nation's first state-regulated medical psilocybin program. This panel spotlights the community-informed pilot study by the Psychedelic Health Equity Initiative (PHEI), designed to center equity, accessibility, and culturally attuned care for underserved communities. Expanding the Lens: Mechanisms, Models & Modes - Transdiagnostic Potential of Psychedelic MedicinesJoin Charles Nichols, Ph.D., and Robin Carhart-Harris, Ph.D., as they unpack the unique mechanisms and models of action that position psychedelics as potential transdiagnostic treatments by addressing shared root causes across conditions. Treating Care Providers and Long COVID with Psychedelic-Assisted TherapyAnthony Back, M.D., moderates a vital discussion with Lawrence Purpura, M.D., Ph.D., Benjamin Lewis, M.D., Kush Bhatt, M.D., and Saleena Subaiya, M.D., on the emerging promise of psychedelic-assisted therapy to help those suffering from long COVID and the burnout experienced by care providers. This session will share clinical updates, innovative approaches, and new possibilities for fostering healing for those on the front lines of care. A Machine Learning Perspective on Psychedelics and PsychopathologyArthur Juliani, Ph.D., shares how artificial intelligence is revolutionizing clinical trial design, protocol optimization, and predictive modeling for psychedelic studies. From Rodents to Humans: Unlocking the Science of Psychedelic-Induced NeuroplasticityModerated by Lindsay Cameron, Ph.D., and featuring Manesh Girn, Ph.D., Max Vargas, Ph.D., and Neil Savalia, M.D./Ph.D(c), this session investigates the limitations of preclinical models in capturing the complexity of human psychedelic experiences and what these challenges mean for the future of psychedelic drug development. Psilocybin Desynchronizes the Human BrainJoin Joshua Siegel, M.D., Ph.D., as he delves into cutting-edge research exploring how psilocybin disrupts established patterns of brain connectivity – unpacking how these transient states of neural desynchronization might illuminate new pathways for therapeutic breakthroughs, and revealing the brain's remarkable flexibility and potential for healing. About Psychedelic SciencePsychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. Facilitated by Superfly, known for producing iconic events such as Bonnaroo and Outside Lands, PS2025 will feature expert speakers; hands-on workshops; community events with art, music, and mindfulness activities; and scholarship opportunities to support broad participation. Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit and follow us on X, Instagram, LinkedIn, and Facebook. ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics. CONTACTmedia@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Dominion Post
4 hours ago
- Dominion Post
Tree of Knowledge: Fairmont State receives Division of Forestry grant for planting project
FAIRMONT – Don't call it 'landscaping.' Fairmont State University last week received a grant from the West Virginia Division of Forestry, which it will use for a tree-planting project on its Locust Avenue campus – but the motivation, participants say, has roots going way deeper. 'The trees themselves are a great project,' architecture major Ryan Williams said. They include the American Holly, Eastern Rosebud, Common Witch Hazel trees, all of which are native to north-central West Virginia, and all planted near the dormitories that line the Campus Drive East entrances, which are currently devoid of greenery. 'But even more than that, I hope it will inspire more students to get involved,' continued Williams, who is on the school's Creative Sustainability Council and helped secure the Community EquiTree grant through the forestry division. 'The more people are engaged with their community and campus,' the student said of the project expected to be completed at month's end, 'the more we can better serve.' And the best way to engage and serve, Williams continued, is by celebrating nature, which is perpetually blooming, growing and evolving. Such celebration, the student said, happens whether we realize it or not. For many, the academic family tree goes back 41 years to 1984, when celebrated biologist and naturalist Edmund O. Wilson wrote and published a slim book he titled, 'Biophilia' – or literally, 'love of life.' 'Life,' in the case of Fairmont State, being what happens on the other side of the classroom wall. Humans, inherently – and unconsciously, even – just 'feel' better in the presence of greenery and trees in places they may not normally be found, the naturalist surmised. Especially, he said, in cities and other locales where concrete, neon and gray buildings prevail. College campuses, too. At the height of the pandemic five years ago, with its student population sequestered under quarantine, Fairmont State did a nod to Wilson. The university created Falcon Park, a walking trail which takes in 7.9 wooded acres at the top of campus and is a haven for native birds, turtles and butterflies. Falcon Park has since been recognized by the National Wildlife Federation. Meanwhile, the most recent tree project, said Devin Carpenter, an assistant construction manager at Fairmont State, will be enjoyed for future generations – aesthetically and environmentally. As the trees grow, he said, their root systems will stabilize hillsides, preventing soil erosion. Their canopies will shade asphalt during the hottest days of summer. And their fall foliage will add to the beauty of campus, Carpenter said. 'And they offer back to nature a piece of what urban development once removed,' he said.


Hamilton Spectator
13 hours ago
- Hamilton Spectator
Ontario health units say measles vaccine registry missing ‘real-time data' on vaccination rates
Under fire for a growing measles outbreak linked to the death of a newborn last week, Health Minister Sylvia Jones is calling on people who are vaccine-resistant to get over it. But public health units in areas hit hard by the highly infectious disease said it's impossible to tell if that's happening because short-term data on measles shots is not immediately available in Ontario's public health system. 'This is a vaccine that has literally existed in the province of Ontario for five decades and when you have two shots you are almost 100 per cent protected. Think about that,' Jones said Tuesday. 'All of us are deeply concerned when we hear of individuals who, for any number of reasons, have chosen not to get vaccinated, some because of allergies, some because of religious and other reasons. It impacts us,' she added. 'This is an opportunity for all of us to understand that our actions have an impact on other people.' The infant who died was born prematurely and was infected in utero through a mother who had not been vaccinated. The newborn was also dealing with other serious health complications. There were renewed calls for Premier Doug Ford's government to step up efforts to fight measles and encourage shots, after Ontario's Chief Medical Officer, Dr. Kieran Moore on Thursday, revealed the fatality last Thursday. However, for now, health units can't tell if the infant's death has spurred more interest in shots, which cannot be taken during pregnancy. 'We do not have the ability to pull real-time data on vaccination uptake over a short window like this, unfortunately,' Southwestern Public Health, where the infant's death occurred, said in a statement to the Star. The health unit is based in St. Thomas to serve Elgin and Oxford counties. 'The majority of vaccination uptake remains at the primary care level, and without a provincial vaccine registry with real-time data, there is no system currently available that can provide this information,' the statement added. Chatham-Kent Public Health said it is also in the dark. 'At present, we do not have data available to assess any shifts in public sentiment regarding the measles vaccine,' said spokesperson Jacquie Cartwright. With the province acknowledging last week there have been six cases of congenital infection in the more than 2,000 cases reported in the province since last October, New Democrat MPP Robin Lennox (Hamilton Centre) said Tuesday the province needs a vaccine registry 'that would help us know who is most vulnerable and where to direct our resources.' The rising infection level shows the government's approach of telling people to see their family doctor or reach out to their local public health unit is not working, Lennox, a family physician, told the Star's Kristin Rushowy last week. 'Obviously, something has broken down, because the advice has been the same for many, many years and this is the only time where we've seen this kind of an outbreak in literally 30 years.' Public health units have held pop-up clinics near schools and churches since the outbreak began. Many of the current cases can be traced to a Mennonite wedding in New Brunswick last fall. Measles had been considered eradicated in Ontario for two decades.